Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.48 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1616050 | 0.97 | TSHR (0.50) | TSHRSOAT1ALDH1A1TDP1MEN1 | |
| SCHEMBL25435787 | 0.86 | TSHR (0.54) | TSHRALDH1A1TDP1MEN1LMNA | |
| SCHEMBL37351 | 0.86 | TSHR (0.54) | TSHRALDH1A1TDP1MEN1LMNA | |
| SCHEMBL11955193 | 0.85 | TSHR (0.50) | TSHRSOAT1ALDH1A1TDP1MEN1 | |
| SCHEMBL6551423 | 0.85 | TSHR (0.45) | TSHRSOAT1ALDH1A1TDP1MEN1 | |
| Ammonia Solution, Strong SCHEMBL9998248 | 0.83 | TSHR (0.52) | TSHRALDH1A1TDP1MEN1LMNA | |
| SCHEMBL21146599 | 0.83 | TSHR (0.48) | TSHRSOAT1ALDH1A1TDP1MEN1 | |
| SCHEMBL5079907 | 0.83 | TSHR (0.43) | TSHRSOAT1ALDH1A1TDP1MEN1 | |
| SCHEMBL304813 | 0.81 | — | — | |
| SCHEMBL631747 | 0.81 | TSHR (0.50) | TSHRALDH1A1TDP1MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771321-B2 | Small molecules that covalently modify transthyretin | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170190660-A9 | Small Molecules That Covalently Modify Transthyretin | KELLY JEFFERY W (US) | 2017-07-06 | — | — | US | disclosed |
| US-20140336254-A1 | Small Molecules That Covalently Modify Transthyretin | KELLY JEFFERY W (US) | 2014-11-13 | — | — | US | disclosed |
| US-8703815-B2 | Small molecules that covalently modify transthyretin | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-04-22 | — | — | US | disclosed |
| US-20120270938-A1 | SMALL MOLECULES THAT COVALENTLY MODIFY TRANSTHYRETIN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-25 | — | — | US | disclosed |
| WO-2011075210-A2 | SMALL MOLECULES THAT COVALENTLY MODIFY TRANSTHYRETIN | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-06-23 | — | — | WO | disclosed |
| US-7094404-B1 | Method for treating malignancy and autoimmune disorders in humans using tac antibodies | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-08-22 | — | — | US | disclosed |
| US-20050207975-A1 | Method for treating malignancy and autoimmune disorders in humans | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH | 2005-09-22 | — | — | US | disclosed |
| EP-0380542-B1 | METHOD FOR TREATING MALIGNANCY AND AUTOIMMUNE DISORDERS IN HUMANS | US COMMERCE (US) | 1996-04-24 | — | — | EP | disclosed |
| EP-0380542-A4 | METHOD FOR TREATING MALIGNANCY AND AUTOIMMUNE DISORDERS IN HUMANS | — | 1990-12-05 | — | — | EP | disclosed |
| EP-0380542-A1 | METHOD FOR TREATING MALIGNANCY AND AUTOIMMUNE DISORDERS IN HUMANS. | US COMMERCE (US) | 1990-08-08 | — | — | EP | disclosed |
| US-4902495-A | IMMUNOTOXIN FOR DETECTION OF MAST CELL ABNORMALITIES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1990-02-20 | — | — | US | disclosed |
| WO-1989001340-A1 | METHOD FOR TREATING MALIGNANCY AND AUTOIMMUNE DISORDERS IN HUMANS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH (US) | 1989-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336254-A1 | Small Molecules That Covalently Modify Transthyretin | TTR, TTPA, APOB | TSHR 1016/4885SOAT1 992/4885ALDH1A1 1584/4885 |
| US-20170190660-A9 | Small Molecules That Covalently Modify Transthyretin | TTR, TTPA, APOB | TSHR 1016/4885SOAT1 992/4885ALDH1A1 1584/4885 |
| US-20120270938-A1 | SMALL MOLECULES THAT COVALENTLY MODIFY TRANSTHYRETIN | TTR, TTPA, APOB | TSHR 1016/4885SOAT1 992/4885ALDH1A1 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.